These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 9392620

  • 1. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan.
    Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun M, Mulcahy RT, Wilding G.
    J Natl Cancer Inst; 1997 Dec 03; 89(23):1789-96. PubMed ID: 9392620
    [Abstract] [Full Text] [Related]

  • 2. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
    Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR.
    J Clin Oncol; 1994 Jan 03; 12(1):194-205. PubMed ID: 8270977
    [Abstract] [Full Text] [Related]

  • 3. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
    O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF.
    J Clin Oncol; 1996 Jan 03; 14(1):249-56. PubMed ID: 8558205
    [Abstract] [Full Text] [Related]

  • 4. Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma.
    Anderson CP, Matthay KK, Perentesis JP, Neglia JP, Bailey HH, Villablanca JG, Groshen S, Hasenauer B, Maris JM, Seeger RC, Reynolds CP.
    Pediatr Blood Cancer; 2015 Oct 03; 62(10):1739-46. PubMed ID: 26153194
    [Abstract] [Full Text] [Related]

  • 5. Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
    Gallo JM, Brennan J, Hamilton TC, Halbherr T, Laub PB, Ozols RF, O'Dwyer PJ.
    Cancer Res; 1995 Oct 15; 55(20):4507-11. PubMed ID: 7553617
    [Abstract] [Full Text] [Related]

  • 6. L-S,R-buthionine sulfoximine: historical development and clinical issues.
    Bailey HH.
    Chem Biol Interact; 1998 Apr 24; 111-112():239-54. PubMed ID: 9679558
    [Abstract] [Full Text] [Related]

  • 7. Potentiation of the cytostatic effect of melphalan on colorectal cancer hepatic metastases by infusion of buthionine sulfoximine (BSO) in the rat: enhanced tumor glutathione depletion by infusion of BSO in the hepatic artery.
    Vahrmeijer AL, van Dierendonck JH, Schutrups J, van de Velde CJ, Mulder GJ.
    Cancer Chemother Pharmacol; 1999 Apr 24; 44(2):111-6. PubMed ID: 10412944
    [Abstract] [Full Text] [Related]

  • 8. Enhancement of melphalan activity by buthionine sulfoximine and electroporation in melanoma cells.
    Ongaro A, Pellati A, De Mattei M, De Terlizzi F, Rossi CR, Campana LG.
    Anticancer Drugs; 2015 Mar 24; 26(3):284-92. PubMed ID: 25514113
    [Abstract] [Full Text] [Related]

  • 9. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line.
    Anderson CP, Seeger RC, Satake N, Monforte-Munoz HL, Keshelava N, Bailey HH, Reynolds CP.
    J Pediatr Hematol Oncol; 2001 Nov 24; 23(8):500-5. PubMed ID: 11878777
    [Abstract] [Full Text] [Related]

  • 10. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
    Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D, Hamilton TC.
    Biochem Pharmacol; 1987 Jan 01; 36(1):147-53. PubMed ID: 3801051
    [Abstract] [Full Text] [Related]

  • 11. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U, Cao S, Minderman H, Toth K, Skenderis BS, Slovak ML, Rustum YM.
    Clin Cancer Res; 1996 Dec 01; 2(12):1961-8. PubMed ID: 9816155
    [Abstract] [Full Text] [Related]

  • 12. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma.
    Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, Maris JM, Hasenauer CE, Czarnecki S, Lai H, Goodarzian F, Shimada H, Reynolds CP.
    Pediatr Blood Cancer; 2016 Aug 01; 63(8):1349-56. PubMed ID: 27092812
    [Abstract] [Full Text] [Related]

  • 13. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
    Siemann DW, Beyers KL.
    Br J Cancer; 1993 Dec 01; 68(6):1071-9. PubMed ID: 8260357
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
    Smith AC, Liao JT, Page JG, Wientjes MG, Grieshaber CK.
    Cancer Res; 1989 Oct 01; 49(19):5385-91. PubMed ID: 2766304
    [Abstract] [Full Text] [Related]

  • 15. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
    Anderson CP, Reynolds CP.
    Bone Marrow Transplant; 2002 Aug 01; 30(3):135-40. PubMed ID: 12189530
    [Abstract] [Full Text] [Related]

  • 16. Melanin content and downregulation of glutathione S-transferase contribute to the action of L-buthionine-S-sulfoximine on human melanoma.
    Fruehauf JP, Zonis S, al-Bassam M, Kyshtoobayeva A, Dasgupta C, Milovanovic T, Parker RJ, Buzaid AC.
    Chem Biol Interact; 1998 Apr 24; 111-112():277-305. PubMed ID: 9679561
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model.
    Neuwelt EA, Pagel MA, Hasler BP, Deloughery TG, Muldoon LL.
    Cancer Res; 2001 Nov 01; 61(21):7868-74. PubMed ID: 11691805
    [Abstract] [Full Text] [Related]

  • 18. Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells.
    Dorr RT, Liddil JD, Soble MJ.
    Invest New Drugs; 1986 Nov 01; 4(4):305-13. PubMed ID: 3583642
    [Abstract] [Full Text] [Related]

  • 19. Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine.
    Skapek SX, VanDellen AF, McMahon DP, Postels DG, Griffith OW, Bigner DD, Friedman HS.
    Cancer Chemother Pharmacol; 1991 Nov 01; 28(1):15-21. PubMed ID: 2040029
    [Abstract] [Full Text] [Related]

  • 20. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results.
    O'Dwyer PJ, Hamilton TC, Young RC, LaCreta FP, Carp N, Tew KD, Padavic K, Comis RL, Ozols RF.
    J Natl Cancer Inst; 1992 Feb 19; 84(4):264-7. PubMed ID: 1734088
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.